How Do SARS-CoV-2 Antivirals Work? Mechanism of Action Explained in Plain English

If you've been prescribed Paxlovid or another COVID-19 antiviral, you might wonder: how exactly does this pill stop a virus? The answer involves a fascinating battle between the drug and the virus at the molecular level. Understanding how these medications work also explains why timing matters so much — and why you can't wait too long to start treatment.

How SARS-CoV-2 Infects and Multiplies in Your Body

To understand how antivirals work, you first need to understand the virus's playbook. When SARS-CoV-2 enters your body, it latches onto cells in your respiratory tract using its characteristic spike protein. Once inside a cell, it hijacks the cell's machinery to make copies of itself — thousands of copies per infected cell. These copies spread to infect more cells, triggering the immune response that causes COVID-19 symptoms.

The key to antiviral treatment is interrupting this copying process before the virus overwhelms your immune system. This is why starting treatment within five days of symptoms — and ideally within three days — is so important. The earlier you interrupt replication, the less virus is in your body, and the less damage it causes.

How Paxlovid Works: Blocking the Virus's Molecular Scissors

Paxlovid (nirmatrelvir/ritonavir) works by targeting an enzyme called the SARS-CoV-2 main protease (also called Mpro, 3CLpro, or nsp5 protease). Think of this enzyme as a pair of molecular scissors that the virus needs to cut a large polyprotein chain into the individual pieces required for viral assembly.

Here's what happens step by step:

1. SARS-CoV-2 enters your cells and starts producing a large protein chain using your cell's ribosomes.
2. The virus's main protease enzyme (Mpro) normally cuts this chain into functional viral proteins, allowing new virus particles to be assembled.
3. Nirmatrelvir — the active antiviral component of Paxlovid — fits into the active site of Mpro like a key in a lock, blocking the enzyme and preventing it from doing its cutting job.
4. Without functional Mpro, the virus cannot make the proteins it needs to assemble new copies of itself. Viral replication grinds to a halt.

What Does Ritonavir Do in Paxlovid?

Paxlovid contains two drugs: nirmatrelvir and ritonavir. Ritonavir is not an antiviral itself in this context — it's a "pharmacokinetic booster." Ritonavir inhibits a liver enzyme called CYP3A4 that would otherwise break down nirmatrelvir too quickly in your body. By blocking CYP3A4, ritonavir allows nirmatrelvir to stay in your bloodstream at effective antiviral levels throughout the five-day treatment course.

This is also the source of Paxlovid's drug interaction issue: because ritonavir inhibits CYP3A4 so powerfully, it can also slow the breakdown of many other medications you might be taking, raising their blood levels to potentially dangerous heights.

Why Paxlovid Works Against New Variants

One of Paxlovid's key advantages over vaccine-based immunity and monoclonal antibodies is that it targets the SARS-CoV-2 main protease — an internal enzyme that is highly conserved across variants. While the virus's spike protein (targeted by vaccines and antibodies) mutates rapidly with each new variant, Mpro is more stable because changes to it are less tolerated by the virus. This is why Paxlovid has maintained efficacy through successive variants.

38,004+ patients found their medications in stock

38K+

Find SARS-CoV-2 Treatment In Stock Today →

How Remdesivir Works: A Different Mechanism

Remdesivir (Veklury) takes a different approach. It's a nucleotide analog — a molecule that mimics one of the building blocks (nucleotides) that the virus uses to copy its genetic material (RNA). When the virus's RNA-dependent RNA polymerase (RdRp) enzyme tries to copy the viral genome, it accidentally incorporates remdesivir instead of the real nucleotide.

Once remdesivir is incorporated, it acts as a "roadblock" — the polymerase enzyme stalls and can no longer continue copying the viral RNA. The result: incomplete, non-functional viral copies that cannot infect new cells.

How Xocova (Ensitrelvir) Works

Xocova (ensitrelvir) uses the same basic approach as Paxlovid — inhibiting the SARS-CoV-2 main protease — but with a key structural difference. Ensitrelvir is designed to work without a ritonavir booster, meaning it can reach therapeutic concentrations on its own. This eliminates the CYP3A4 inhibition problem, resulting in significantly fewer drug interactions than Paxlovid.

Skip the calls, skip the stress.

Find SARS-CoV-2 Treatment In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Why the Five-Day Window Is Critical

COVID-19 antivirals work by stopping viral replication — but they can only stop replication that hasn't happened yet. If you wait too long to start treatment, the virus has already made millions or billions of copies of itself. By Day 5 or 6 of symptoms, the viral load is often already declining naturally, and antiviral treatment has less to work with. Starting treatment within the first three days maximizes the drug's impact on viral replication.

For a full overview of COVID-19 antiviral options including dosing and eligibility, see our guide on what SARS-CoV-2 antivirals are and how to get them in 2026.